{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:11:59Z","timestamp":1778667119993,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Women harboring pathogenic variant (PV) in the\n                    <jats:italic>BRCA1<\/jats:italic>\n                    or\n                    <jats:italic>BRCA2<\/jats:italic>\n                    genes (=\u2009\n                    <jats:italic>BRCA<\/jats:italic>\n                    ) have an elevated lifetime risk for breast cancer (BC). One of the main options for active BC risk reduction is bilateral risk-reducing mastectomy (RRM). Understanding the factors influencing that decision is important for genetic-counselling and risk mitigation strategy planning. A structured questionnaire was circulated to\n                    <jats:italic>BRCA<\/jats:italic>\n                    carriers, members of the Good Genes NGO in Israel. Data on RRM uptake and timing, factors previously reported to be associated with decision to undergo RRM (e.g., psychosocial, family history, counselling\/health-system factors) were obtained. Comparison between carriers who elected to undergo RRM with those who opted for early detection schemes were performed using logistic regression and chi square statistical analyses. Of cancer free women (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009391), 272 (69.6%) elected to adhere to the recommended surveillance scheme and 119 (30.4%) elected to undergo RRM. The major reasons for electing RRM over surveillance were active BC risk reduction (4.96\u2009\u00b1\u20090.23), fear of developing BC (4.86\u2009\n                    <jats:italic>\u00b1<\/jats:italic>\n                    \u20090.50), and having at least one relative with BC diagnosed under age 45 years. Support group discussions emerged as a stronger determinant of RRM uptake than primary care physician or religious guidance. In conclusion, among healthy Israeli\n                    <jats:italic>BRCA<\/jats:italic>\n                    carriers the decision to undergo RRM was influenced by a complex interplay of factors\u2014active BC risk reduction, fear of cancer diagnosis in the context of having one relative with early onset BC and support group discussions were the major drivers of RRM in Israeli\n                    <jats:italic>BRCA1<\/jats:italic>\n                    carriers.\n                  <\/jats:p>","DOI":"10.1007\/s10689-026-00568-x","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:23:19Z","timestamp":1778664199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors influencing uptake of risk-reducing mastectomy among unaffected Israeli BRCA1\/BRCA2 pathogenic variant carriers"],"prefix":"10.1007","volume":"25","author":[{"given":"Yael","family":"Laitman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Aharon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talia","family":"Schloss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libby","family":"Margolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eitan","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"issue":"23","key":"568_CR1","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402\u20132416","journal-title":"JAMA"},{"issue":"6","key":"568_CR2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3390\/life14060777","volume":"14","author":"L Katsika","year":"2024","unstructured":"Katsika L, Boureka E, Kalogiannidis I, Tsakiridis I, Tirodimos I, Lallas K, Tsimtsiou Z, Dagklis T (2024) Screening for breast cancer: a comparative review of guidelines. Life (Basel) 14(6):777. https:\/\/doi.org\/10.3390\/life14060777","journal-title":"Life (Basel)"},{"key":"568_CR3","unstructured":"NCCN guidelines. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast-screening.pdf"},{"issue":"1","key":"568_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","volume":"34","author":"C Sessa","year":"2023","unstructured":"Sessa C, Balma\u00f1a J, de Azambuja E, Sonke GS, Paluch-Shimon S, Cardoso F et al (2023) Risk reduction and screening of cancer in hereditary breast\u2013ovarian cancer syndromes: ESMO clinical practice guideline. Ann Oncol 34(1):33\u201347. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.004","journal-title":"Ann Oncol"},{"key":"568_CR5","unstructured":"https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=2&id=1545&utm_source"},{"issue":"5","key":"568_CR6","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.3390\/cancers15051625","volume":"15","author":"F Gaba","year":"2023","unstructured":"Gaba F, Piek J, Manchanda R, Dyer R, Smrkolj \u0160, Sarid Mogilevsky S et al (2023) Breast cancer risk and breast-cancer-specific mortality following risk-reducing salpingo-oophorectomy in BRCA carriers: a systematic review and meta-analysis. Cancers (Basel) 15(5):1625. https:\/\/doi.org\/10.3390\/cancers15051625","journal-title":"Cancers (Basel)"},{"issue":"1","key":"568_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41416-019-0446-1","volume":"121","author":"K Metcalfe","year":"2019","unstructured":"Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS et al (2019) International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer 121(1):15\u201321","journal-title":"Br J Cancer"},{"key":"568_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-025-07821-4","author":"CB Willert","year":"2025","unstructured":"Willert CB, Mellemkj\u00e6r L, Tolver A, Gerdes A-MA, Rosth\u00f8j S, Wadt K et al (2025) Time trends, uptake, and oncological effects of risk-reducing surgeries in 3067 Danish BRCA1\/2 carriers: a population-based study with matched controls. Breast Cancer Res Treat. [Epub ahead of print] https:\/\/doi.org\/10.1007\/s10549-025-07821-4","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"568_CR9","doi-asserted-by":"publisher","first-page":"109571","DOI":"10.1016\/j.ejso.2024.109571","volume":"51","author":"HK Hyldebrandt","year":"2025","unstructured":"Hyldebrandt HK, Stormorken AT, Vitelli V, M\u00e6hle L, Schlichting E, Grindedal EM (2025) Risk reducing mastectomy in Norwegian BRCA1\/2 carriers. Eur J Surg Oncol 51(3):109571. https:\/\/doi.org\/10.1016\/j.ejso.2024.109571","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"568_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/jmedgenet-2020-107387","volume":"58","author":"DGR Evans","year":"2021","unstructured":"Evans DGR, Howell A, Ward D, Prestwich F, Betterton J, Duffy SW et al (2021) Twenty-year experience of breast-cancer risk management in the U.K. familial-risk program. J Med Genet 58(5):329\u2013336. https:\/\/doi.org\/10.1136\/jmedgenet-2020-107387","journal-title":"J Med Genet"},{"issue":"4","key":"568_CR11","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.3390\/cancers15041072","volume":"15","author":"M Zimovjanova","year":"2023","unstructured":"Zimovjanova M, Skapa P, Fedorova L, Horak J, Brandejsova J, Foretova L (2023) Uptake and effectiveness of risk-reducing surgeries in unaffected female BRCA1 and BRCA2 carriers: a single institution experience in the Czech Republic. Cancers (Basel) 15(4):1072. https:\/\/doi.org\/10.3390\/cancers15041072","journal-title":"Cancers (Basel)"},{"issue":"7","key":"568_CR12","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.3390\/cancers14071786","volume":"14","author":"JS Sim\u00f5es Corr\u00eaa Galendi","year":"2022","unstructured":"Sim\u00f5es Corr\u00eaa Galendi JS, Kautz-Freimuth S, Stock S, M\u00fcller D (2022) Uptake rates of risk-reducing surgeries for women at increased risk of hereditary breast and ovarian cancer applied to cost-effectiveness analyses: a scoping systematic review. Cancers (Basel) 14(7):1786. https:\/\/doi.org\/10.3390\/cancers14071786","journal-title":"Cancers (Basel)"},{"issue":"3","key":"568_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000503370","volume":"15","author":"R Segerer","year":"2020","unstructured":"Segerer R, Steinke-Lange V, Kurz C, Dworniczak B, Rahner N, Hinterberger-Fischer M et al (2020) Factors impacting on decision-making towards prophylactic surgeries in BRCA mutation carriers and women with familial predisposition. Breast Care (Basel) 15(3):253\u2013259. https:\/\/doi.org\/10.1159\/000503370","journal-title":"Breast Care (Basel)"},{"issue":"4","key":"568_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.4069\/kjwhn.2020.11.19","volume":"26","author":"S Park","year":"2020","unstructured":"Park S, Kim Y, Kim S (2020) Factors associated with the decision to undergo risk-reducing salpingo-oophorectomy among women at high risk for hereditary breast and ovarian cancer: a systematic review. Korean J Women Health Nurs 26(4):285\u2013299. https:\/\/doi.org\/10.4069\/kjwhn.2020.11.19","journal-title":"Korean J Women Health Nurs"},{"issue":"4","key":"568_CR15","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/pon.6111","volume":"32","author":"A Isselhard","year":"2023","unstructured":"Isselhard A, Niels T, Antoniadis A, Becker K, Kohls E, Nothacker J et al (2023) Psychological distress and decision-making factors for prophylactic bilateral mastectomy in cancer-unaffected BRCA1\/2 pathogenic variant carriers. Psychooncology 32(4):640\u2013648. https:\/\/doi.org\/10.1002\/pon.6111","journal-title":"Psychooncology"},{"key":"568_CR16","doi-asserted-by":"publisher","first-page":"e2400097","DOI":"10.1200\/GO.24.00097","volume":"10","author":"Y Chavarri-Guerra","year":"2024","unstructured":"Chavarri-Guerra Y, Villarreal-Garza C, Lazcano-Ponce E, Banegas MP, Flores-Luna L, Komenaka I et al (2024) Uptake of risk-reducing surgeries in an international real-world cohort of Hispanic women. JCO Glob Oncol 10:e2400097. https:\/\/doi.org\/10.1200\/GO.24.00097","journal-title":"JCO Glob Oncol"},{"issue":"6","key":"568_CR17","doi-asserted-by":"publisher","first-page":"e076876","DOI":"10.1136\/bmjopen-2023-076876","volume":"14","author":"SA McGarrigle","year":"2024","unstructured":"McGarrigle SA, Prizeman G, Spillane C, Byrne N, Drury A et al (2024) Decision aids for female BRCA mutation carriers: a scoping review. BMJ Open 14(6):e076876. https:\/\/doi.org\/10.1136\/bmjopen-2023-076876","journal-title":"BMJ Open"},{"issue":"1","key":"568_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/cge.12149","volume":"85","author":"Y Laitman","year":"2014","unstructured":"Laitman Y, Feng B, Zamir IM, Levi R, Friedman E, Kaufman B et al (2014) Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers. Clin Genet 85(1):68\u201371. https:\/\/doi.org\/10.1111\/cge.12149","journal-title":"Clin Genet"},{"issue":"4","key":"568_CR19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10689-006-0002-z","volume":"5","author":"V Kram","year":"2006","unstructured":"Kram V, Peretz T, Sagi M, Levy-Lahad E, Friedman E (2006) Acceptance of preventive surgeries by Israeli women who had undergone BRCA testing. Fam Cancer 5(4):327\u2013335. https:\/\/doi.org\/10.1007\/s10689-006-0002-z","journal-title":"Fam Cancer"},{"issue":"2","key":"568_CR20","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/ijgc-2023-004801","volume":"34","author":"C Nahshon","year":"2024","unstructured":"Nahshon C, Segev Y, Schmidt M, Lavie O (2024) Attitude of BRCA1\/2 mutation carriers towards surgical risk reduction for breast, ovarian and uterine cancer: still much to be done. Int J Gynecol Cancer 34(2):260\u2013266. https:\/\/doi.org\/10.1136\/ijgc-2023-004801","journal-title":"Int J Gynecol Cancer"},{"key":"568_CR21","doi-asserted-by":"publisher","first-page":"e2300417","DOI":"10.1200\/GO.23.00417","volume":"10","author":"F Mesa-Chavez","year":"2024","unstructured":"Mesa-Chavez F, Chavarri-Guerra Y, Aguilar-Y-Mendez D, Becerril-Gaitan A, Vaca-Cartagena BF, Carrillo-Bedoya A et al (2024) Uptake of risk-reducing measures, cascade testing, and related challenges among carriers of breast cancer-associated germline pathogenic variants in Mexico. JCO Glob Oncol 10:e2300417. https:\/\/doi.org\/10.1200\/GO.23.00417","journal-title":"JCO Glob Oncol"},{"issue":"1","key":"568_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1308\/rcsann.2023.0042","volume":"106","author":"J Morgan","year":"2024","unstructured":"Morgan J, Lugg-Widger F, Rylance A, Rice C, Lewis K, Edwards A et al (2024) Psychosocial outcomes after varying risk management strategies in women at increased familial breast cancer risk: a mixed methods study of patient and partner outcomes. Ann R Coll Surg Engl 106(1):78\u201391. https:\/\/doi.org\/10.1308\/rcsann.2023.0042","journal-title":"Ann R Coll Surg Engl"},{"issue":"3","key":"568_CR23","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3390\/jcm8030313","volume":"8","author":"P Modaffari","year":"2019","unstructured":"Modaffari P, Ponzone R, Ferrari A, Cipullo I, Liberale V, D\u2019Alonzo M, Maggiorotto F, Biglia N (2019) Concerns and expectations of risk-reducing surgery in women with hereditary breast and ovarian cancer syndrome. J Clin Med 8(3):313. https:\/\/doi.org\/10.3390\/jcm8030313","journal-title":"J Clin Med"},{"issue":"1","key":"568_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1214\/aoms\/1177730491","volume":"18","author":"HB Mann","year":"1947","unstructured":"Mann HB, Whitney DR (1947) On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat 18(1):50\u201360","journal-title":"Ann Math Stat"},{"issue":"7","key":"568_CR25","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/sim.4780090710","volume":"9","author":"Y Hochberg","year":"1990","unstructured":"Hochberg Y, Benjamini Y (1990) More powerful procedures for multiple significance testing. Stat Med 9(7):811\u2013818. https:\/\/doi.org\/10.1002\/sim.4780090710","journal-title":"Stat Med"},{"issue":"5","key":"568_CR26","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10459-010-9222-y","volume":"15","author":"G Norman","year":"2010","unstructured":"Norman G (2010) Likert scales, levels of measurement and the laws of statistics. Adv Health Sci Educ 15(5):625\u2013632","journal-title":"Adv Health Sci Educ"},{"issue":"2","key":"568_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/ng1096-185","volume":"14","author":"BB Roa","year":"1996","unstructured":"Roa BB, Boyd AA, Volcik K, Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14(2):185\u2013187. https:\/\/doi.org\/10.1038\/ng1096-185","journal-title":"Nat Genet"},{"issue":"3","key":"568_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.tjem.2018.08.001","volume":"18","author":"H Akoglu","year":"2018","unstructured":"Akoglu H (2018) User\u2019s guide to correlation coefficients. Turk J Emerg Med 18(3):91\u201393. https:\/\/doi.org\/10.1016\/j.tjem.2018.08.001","journal-title":"Turk J Emerg Med"},{"issue":"12","key":"568_CR29","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1001\/jamaoncol.2023.5029","volume":"9","author":"BAM Heemskerk-Gerritsen","year":"2023","unstructured":"Heemskerk-Gerritsen BAM, Jager A, Koppert LB, Obdeijn IM, Coll\u00e9e JM, Meijers-Heijboer HEJ et al (2023) Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. JAMA Oncol 9(12):1687\u20131694. https:\/\/doi.org\/10.1001\/jamaoncol.2023.5029","journal-title":"JAMA Oncol"},{"issue":"4","key":"568_CR30","doi-asserted-by":"publisher","first-page":"CD002748","DOI":"10.1002\/14651858.CD002748.pub4","volume":"4","author":"NE Carbine","year":"2018","unstructured":"Carbine NE, Lostumbo L, Wallace J, Ko H (2018) Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev 4(4):CD002748. https:\/\/doi.org\/10.1002\/14651858.CD002748.pub4","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"568_CR31","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13053-022-00244-y","volume":"20","author":"J Dick","year":"2022","unstructured":"Dick J, Ablasser G, Ehlers M, Steinemann N, Schulze S, Preisler-Adams S et al (2022) Psychological factors and the uptake of preventative measures in BRCA1\/2 pathogenic variant carriers: results of a prospective cohort study. Hered Cancer Clin Pract 20(1):38. https:\/\/doi.org\/10.1186\/s13053-022-00244-y","journal-title":"Hered Cancer Clin Pract"},{"issue":"7","key":"568_CR32","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1037\/hea0000156","volume":"34","author":"DB Portnoy","year":"2015","unstructured":"Portnoy DB, Loud JT, Han PKJ, Mai PL, Greene MH (2015) Effects of false-positive cancer screenings and cancer worry on risk-reducing surgery among BRCA1\/2 mutation carriers. Health Psychol 34(7):709\u2013717. https:\/\/doi.org\/10.1037\/hea0000156","journal-title":"Health Psychol"},{"issue":"1","key":"568_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13058-017-0826-5","volume":"19","author":"TJ Padamsee","year":"2017","unstructured":"Padamsee TJ, Wills CE, Yee LD, Paskett ED (2017) Decision making for breast cancer prevention among women at elevated risk. Breast Cancer Res 19(1):34. https:\/\/doi.org\/10.1186\/s13058-017-0826-5","journal-title":"Breast Cancer Res"},{"issue":"10","key":"568_CR34","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1245\/s10434-017-5976-2","volume":"24","author":"E Gilbert","year":"2017","unstructured":"Gilbert E, Zabor EC, Stempel M, Mangino DA, Kellick MG, Morrow M et al (2017) Differences among a modern cohort of BRCA mutation carriers choosing bilateral prophylactic mastectomies compared to breast surveillance. Ann Surg Oncol 24(10):3048\u20133054. https:\/\/doi.org\/10.1245\/s10434-017-5976-2","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"568_CR35","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ajog.2013.01.026","volume":"208","author":"K Singh","year":"2013","unstructured":"Singh K, Lester J, Karlan B, Bresee C, Geva T, Gordon O (2013) Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers. Am J Obstet Gynecol 208(4):329. e1-6","journal-title":"Am J Obstet Gynecol"},{"key":"568_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.socscimed.2016.06.039","volume":"163","author":"M Dean","year":"2016","unstructured":"Dean M (2016) It\u2019s not if I get cancer, it\u2019s when I get cancer: BRCA-positive patients\u2019 (un)certain health experiences regarding hereditary breast and ovarian cancer risk. Soc Sci Med 163:21\u201327. https:\/\/doi.org\/10.1016\/j.socscimed.2016.06.039","journal-title":"Soc Sci Med"},{"key":"568_CR37","doi-asserted-by":"publisher","unstructured":"Dean M, Fisher CL (2019) Uncertainty and previvors\u2019 cancer risk management: understanding the decision-making process. J Appl Commun Res 47(4):460\u2013483. https:\/\/doi.org\/10.1080\/00909882.2019.1657236","DOI":"10.1080\/00909882.2019.1657236"},{"issue":"12","key":"568_CR38","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1177\/1049732312458182","volume":"22","author":"LM Hoskins","year":"2012","unstructured":"Hoskins LM, Greene MH (2012) Anticipatory loss and early mastectomy for young female BRCA1\/2 mutation carriers. Qual Health Res 22(12):1633\u20131646. https:\/\/doi.org\/10.1177\/1049732312458182","journal-title":"Qual Health Res"},{"issue":"3","key":"568_CR39","doi-asserted-by":"publisher","first-page":"e6311","DOI":"10.1002\/pon.6311","volume":"33","author":"C Torrisi","year":"2024","unstructured":"Torrisi C, Wareg NK, Brandt Anbari A (2024) Decision-making for bilateral risk-reducing mastectomy for an increased lifetime breast cancer risk: a qualitative metasynthesis. Psychooncology 33(3):e6311. https:\/\/doi.org\/10.1002\/pon.6311","journal-title":"Psychooncology"},{"issue":"1","key":"568_CR40","first-page":"51","volume":"21","author":"B Bertonazzi","year":"2022","unstructured":"Bertonazzi B, Bellati F, Ricciardi E, Capriglione S, Perrone E, Di Meglio A et al (2022) Outcomes of support groups for carriers of BRCA1\/2. Fam Cancer 21(1):51\u201361","journal-title":"Fam Cancer"},{"key":"568_CR41","doi-asserted-by":"publisher","first-page":"100989","DOI":"10.1016\/j.gore.2022.100989","volume":"41","author":"KE Dibble","year":"2022","unstructured":"Dibble KE, Donorfio LKM, Britner PA, Bellizzi KM (2022) Perceptions and care Recommendations from Previvors: Qualitative analysis of female BRCA1\/2 mutation Carriers\u2019 experience with genetic testing and counseling. Gynecol Oncol Rep 41:100989. https:\/\/doi.org\/10.1016\/j.gore.2022.100989","journal-title":"Gynecol Oncol Rep"},{"issue":"2","key":"568_CR42","first-page":"179","volume":"27","author":"F Gaba","year":"2021","unstructured":"Gaba F, Manchanda R, Smrkolj S, Sarid Mogilevsky S, Seckl MJ, McCluggage WG et al (2021) Surgical decision-making in premenopausal BRCA carriers: the influence of online support forums. Breast J 27(2):179\u2013188","journal-title":"Breast J"},{"issue":"5","key":"568_CR43","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s10897-018-0254-4","volume":"27","author":"A Puski","year":"2018","unstructured":"Puski A, Hovick S, Senter L, Toland AE (2018) Involvement and influence of healthcare providers, family members, and other mutation carriers in the cancer risk management decision-making process of BRCA1 and BRCA2 mutation carriers. J Genet Couns 27(5):1291\u20131301. https:\/\/doi.org\/10.1007\/s10897-018-0254-4","journal-title":"J Genet Couns"},{"issue":"10","key":"568_CR44","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1177\/1049732318785372","volume":"28","author":"R Graham","year":"2018","unstructured":"Graham R, Owens M, Priest H, Hutton S (2018) Constructions of decision making for risk-reducing mastectomy. Qual Health Res 28(10):1595\u20131609. https:\/\/doi.org\/10.1177\/1049732318785372","journal-title":"Qual Health Res"},{"issue":"5","key":"568_CR45","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1007\/s10897-015-9929-2","volume":"25","author":"S Hesse-Biber","year":"2016","unstructured":"Hesse-Biber S, An C (2016) Genetic testing and post-testing decision making among BRCA-positive mutation women: a psychosocial approach. J Genet Couns 25(5):978\u2013992. https:\/\/doi.org\/10.1007\/s10897-015-9929-2","journal-title":"J Genet Couns"},{"issue":"4","key":"568_CR46","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1001\/jamaoncol.2023.6944","volume":"10","author":"J Lubinski","year":"2024","unstructured":"Lubinski J, Kotsopoulos J, Moller P, Pal T, Eisen A, Peck L et al (2024) MRI surveillance and breast cancer mortality in women with BRCA1 and BRCA2 sequence variations. JAMA Oncol 10(4):493\u2013499. https:\/\/doi.org\/10.1001\/jamaoncol.2023.6944","journal-title":"JAMA Oncol"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-026-00568-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-026-00568-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-026-00568-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:23:23Z","timestamp":1778664203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-026-00568-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["568"],"URL":"https:\/\/doi.org\/10.1007\/s10689-026-00568-x","relation":{},"ISSN":["1573-7292"],"issn-type":[{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the local ethics committee (SMC 1492-14), and all participants consented for participation prior to completing the questionnaire, as implied by consent completion, in compliance with the IRB approved protocol.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"54"}}